Medpace Holdings (MEDP): Rasio utang marang kapitalisasi buku

Medpace Holdings, Inc. (MEDP) generates revenue from multi-year contracts with biotech companies, which has created upward momentum. On GURU.Markets, the share of debt financing in the balance sheet capitalization reached a peak, after which 0.29 records the current value of the indicator. Business stability is supported by a global network of proprietary laboratories and a neutral geopolitical status within the humanitarian sector of clinical research.

MEDP Medpace Corp: Utang marang nilai buku ing interval 04.07.2022 - 29.10.2026

Rincian metrik komprehensif lan analitis Medpace Holdings (MEDP)

- rega saiki lan proyeksi nilai saham:

Rega saham Medpace Holdings, Inc.|MEDP - Prakiraan konsensus analis

- data kapitalisasi bursa:

Nilai pasar Medpace Corp|MEDP - Nilai Dipunlarasaken Utang lan Kas

- indikator nilai buku ekuitas:

Aset Bersih saben Siji Saham Medpace|MEDP - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku medpace.com|MEDP - Total Aset Perusahaan

- informasi babagan utang lan solvabilitas:

Rasio Total Utang marang Ekuitas Medpace Holdings, Inc.|MEDP - Koefisien utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Medpace Inc.|MEDP - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Medpace Corp|MEDP - Utang jangka dawa|Utang jangka cendhak perusahaan Medpace|Indikator likuiditas cepet medpace.com

- data bathi bisnis lan rasio investasi:

MEDP - Bathi sawise mbayar pajeg

Analisis umum perusahaan:Medpace Holdings, Inc. MEDP

Medpace Holdings, Inc. (MEDP) maintains an impeccable reputation in the clinical research sector, minimizing systemic risks and transforming operational efficiency into a foundation for financial stability. By analyzing the extent to which balance sheet capital covers debt obligations, an investor evaluates the total debt-to-equity ratio; low values for this metric confirm the issuer's high solvency and its capacity for expansion without incurring a critical credit burden.

Analisis pesaing

Utang-utang marang kapitalisasi buku IQV (IQVIA Holdings Inc.)|Utang-utang marang kapitalisasi buku labcorp.com LH|ICLR - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik CRL (Charles River Laboratories International, Inc.)|Evotec Corp (EVO) - Rasio utang marang kapitalisasi buku|Utang marang nilai buku Fortrea Clinical|LFCR (Lifecore Biomedical Inc.) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku omniab.com|Utang marang nilai buku NOTV (Inotiv)|CDMO (Avid Bioservices Inc.) - Rasio utang marang aset resik|Catalent Pharma Solutions - Utang marang nilai buku|Utang marang modal buku SCPX (Scorpius Holdings, Inc)